Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 5/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TERT | O14746 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21694121 | 0.83 | APOBEC3A (0.49) | APOBEC3AAPOBEC3GLMNASLC18A3CDC25A | |
| Hydrochloric Acid SCHEMBL4326082 | 0.83 | APOBEC3A (0.49) | APOBEC3AAPOBEC3GLMNASLC18A3CDC25A | |
| SCHEMBL10556416 | 0.81 | APOBEC3A (0.72) | APOBEC3AAPOBEC3GLMNASLC18A3PABPC1 | |
| SCHEMBL21694128 | 0.80 | APOBEC3A (0.49) | APOBEC3AAPOBEC3GSLC18A3CDC25APABPC1 | |
| Bromide SCHEMBL9056128 | 0.79 | APOBEC3A (0.70) | APOBEC3AAPOBEC3GLMNASLC18A3PABPC1 | |
| SCHEMBL13108406 | 0.78 | APOBEC3A (0.48) | APOBEC3AAPOBEC3GSLC18A3CDC25APABPC1 | |
| SCHEMBL13964661 | 0.77 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GLMNASLC18A3CDC25A | |
| SCHEMBL11583345 | 0.77 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GLMNASLC18A3CDC25A | |
| SCHEMBL12633575 | 0.76 | SLC18A3 (0.60) | APOBEC3AAPOBEC3GLMNASLC18A3GAA | |
| SCHEMBL1223460 | 0.74 | KDM4E (0.59) | APOBEC3AAPOBEC3GCDC25APABPC1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | APOBEC3A 245/4885APOBEC3G 602/4885LMNA 692/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | APOBEC3A 289/4885APOBEC3G 282/4885LMNA 624/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | APOBEC3A 85/4885APOBEC3G 71/4885LMNA 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.